Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Seeking Guidance On Abuse-Deterrence: Sponsors Fall Short, Congress Urges Action

This article was originally published in RPM Report

Executive Summary

Congressional appropriators are urging FDA to move quickly to finalize guidance on abuse deterrence claims for opioids—and to take the next step and prohibit marketing of products that don’t deter abuse. FDA says the science isn’t there yet, and two sponsors join the list of those who have failed to clear the hurdle.

You may also be interested in...

FDA Funding Helped By Ebola Emergency Spending, But Opioid Issue Still Rankles Appropriators

Spending agreement includes $137 more for FDA—most from user fee increases previously enacted. Still, discretionary budget does go up for FDA, albeit at the cost of a rider demanding final action on abuse-deterrent formulation guidance by June.

Pfizer Gets Abuse-Deterrent Claim on One Pain Drug, Then Drops Development of Another

Pfizer got its first abuse-deterrent claim for its pain therapy Embeda. But it has also ended an agreement to develop another potential abuse-deterrent pain drug.

FDA May Emerge From Zohydro Approval Purgatory in October

FDA could get relief this autumn from a year of political controversy stemming from the approval of Zohydro, thanks to two abuse-deterrent hydrocodone applications in the works from Purdue and Zogenix. 

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts